Is community-acquired pneumonia an independent risk factor for cardiovascular disease?

European Respiratory Journal

Volumn 39, Issue 1, 2012, Pages 187-196

  Singanayagam, A ^a,b   Elder, D H J ^c   Chalmers, J D ^d  

^a CHASE FARM HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Atherosclerosis; Community acquired pneumonia; Infection; Myocardial infarction

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CORONARY ARTERY CONSTRICTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; HEART DEATH; HIGH RISK PATIENT; HUMAN; OXYGEN CONSUMPTION; OXYGEN SUPPLY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR DISEASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; CORONARY VESSELS; HUMANS; INFECTION; INFLAMMATION; MYOCARDIAL INFARCTION; OXYGEN; PLATELET ACTIVATION; PNEUMONIA; RISK; RISK FACTORS; THROMBOSIS;

EID: 84855380599     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00049111     Document Type: Review

References (108)

1. World Health Organization. The Top Ten Causes of Death. www.who.int/mediacentre/factsheets/fs310.pdf Last updated: February 2007. Date last accessed: November 30, 2010.
2. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162: 1059-1064. (Pubitemid 34492537)
3. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122: 130-141.
4. Brito V, Niederman MS. Predicting mortality in the elderly with community-acquired pneumonia: should we design a new car or set a new "speed limit"? Thorax 2010; 65: 944-945.
5. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275: 134-141.
6. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010; 65: 878-883.
7. From the Centers for Disease Control and Prevention. Pneumonia and influenza death rates - United States, 1979-1994. JAMA 1995; 274: 532.
8. Mortensen EM, Kapoor WN, Chang CC, et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37: 1617-1624. (Pubitemid 37549947)
9. Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008; 87: 329-334.
10. Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on long term mortality after pneumonia in older people. J Am Geriatr Soc 2007; 55: 518-525. (Pubitemid 46496572)
11. Bruns AH, Oosterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect 2011; 17: 763-768.
12. Koivula I, Stén M, Mäkelä PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999; 159: 1550-1555. (Pubitemid 29340308)
13. Chalmers JD. ICU admission and severity assessment in community-acquired pneumonia. Crit Care 2009; 13: 156.
14. Kannel WB, Gordan T. Evaluation of cardiovascular risk in the elderly: the Framingham study. Bull NY Acad Med 1978; 54: 573-591. (Pubitemid 9159497)
15. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569. (Pubitemid 24182120)
16. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126. (Pubitemid 29054847)
17. Farmer JA, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler Rep 2002; 4: 92-98.
18. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890. (Pubitemid 34219736)
19. Boyle JJ. Association of coronary plaque rupture and atherosclerotic inflammation. J Pathol 1997; 181: 93-99. (Pubitemid 27099780)
20. Arbustini E, Morbini P, Bello BD, et al. From plaque biology to clinical setting. Am Heart J 1999; 138: S55-S60. (Pubitemid 29379642)
21. Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Rev 2000; 8: 31-39. (Pubitemid 30053979)
22. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482. (Pubitemid 28228207)
23. Biasucci L, Liuzzo G, Angiolillo D, et al. Inflammation and acute coronary syndromes. Herz 2000; 25: 108-112. (Pubitemid 30238976)
24. Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55: 445-451. (Pubitemid 34462239)
25. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol 2010; 105: 1284-1288.
26. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818. (Pubitemid 32291421)
27. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363.
28. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-2610. (Pubitemid 39628581)
29. Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003; 107: 2016-2020. (Pubitemid 36506076)
30. Yeh ET. High-sensitivity C reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol 2005; 28: 408-412. (Pubitemid 41254302)
31. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242. (Pubitemid 29056365)
32. Nyandak T, Gogna A, Bansal S, et al. High sensitive C-reactive protein (hs-CRP) and its correlation with angiographic severity of coronary artery disease (CAD). J Ind Acad Clin Med 2007; 8: 217-221. (Pubitemid 47395105)
33. Katritsis D, Korovesis S, Giazitzoglou E, et al. C-reactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem 2001; 47: 882-886. (Pubitemid 32398039)
34. Tataru MC, Heinrich J, Junker R, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21: 1000-1008. (Pubitemid 30312089)
35. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997; 78: 273-277. (Pubitemid 27431736)
36. Patterson CC, Smith AE, Yarnell JW, et al. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis 2010; 209: 551-557.
37. Kelleher CC. Plasma fibrinogen and factor VII as risk factors for cardiovascular disease. Eur J Epidemiol 1992; 8: Suppl. 1, 79-82.
38. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177: 1242-1247. (Pubitemid 351860933)
39. Madjid M, Vela D, Khalili-Tabrizi H, et al. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes. Tex Heart Inst J 2007; 34: 11-18. (Pubitemid 46588479)
40. Zhang G, Han J, Welch EJ, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 2009; 182: 7997-8004.
41. Lassila R, Badimon JJ, Vallabhajosula S, et al. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenoses on thrombus growth. Arteriosclerosis 1990; 10: 306-315. (Pubitemid 20103594)
42. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010; 67: 525-544.
43. Puren AJ, Feldman C, Savage N, et al. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995; 107: 1342-1349.
44. Antunes G, Evans SA, Lordan JL, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002; 20: 990-995. (Pubitemid 35175139)
45. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655-1663. (Pubitemid 47280347)
46. Gando S, Kameue T, Morimoto Y, et al. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002; 30: 1729-1934.
47. Milbrandt EB, Reade MC, LeeM, et al. Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 2009; 15: 438-445.
48. Kale S, Yende S, Kong L, et al. The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalised for pneumonia. PLOS One 2010; 5: e13852.
49. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997; 349: 1391-1392. (Pubitemid 27197552)
50. Shapiro NI, Schuetz P, Yano K, et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 2010; 14: R182.
51. Kirkebøen K, Strand OA. The role of nitric oxide in sepsis - an overview. Acta Anaesthesiol Scand 1999; 43: 275-288. (Pubitemid 29109473)
52. Preiser JC, Zhang H, Vray B, et al. Time course of inducible nitric oxide synthase activity following endotoxin administration in dogs. Nitric Oxide 2001; 5: 208-211. (Pubitemid 34142744)
53. Khadour FH, Panas D, Ferdinandy P, et al. Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol Heart Circ Physiol 2002; 283: H1108-H1115.
54. Merx MW, Weber C. Sepsis and the heart. Circulation 2007; 116: 793-802. (Pubitemid 47255997)
55. Parratt JR. Nitric oxide in sepsis and endotoxaemia. J Antimicrob Chemother 1998; 41: Suppl. A, 31-39.
56. Kelm M, Schäfer S, Dahmann R, et al. Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generation. Cardiovasc Res 1997; 36: 185-194. (Pubitemid 27527343)
57. Lee WL, Liles WC. Endothelial activation, dysfunction and permeability during severe infections. Curr Opin Hematol 2011; 18: 191-196.
58. Ullrich R, Scherrer-Crosbie M, Bloch KD, et al. Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocardial dysfunction in mice. Circulation 2000; 102: 1440-1446.
59. Liu SF, Newton R, Evans TW, et al. Differential regulation of cyclo-oxygenase-I and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci (Lond) 1996; 90: 301-306.
60. Reines HD, Halushka PV, Cook JA, et al. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 1982; 320: 174-175. (Pubitemid 12080516)
61. Shindo T, Kurihara H, Kurihara Y, et al. Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. J Cardiovasc Pharmacol 1998; 31: S541-S544. (Pubitemid 128710006)
62. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
63. Maeder M, Fehr T, Rickli H, et al. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129: 1349-1366.
64. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock. Crit Care Clin 2000; 16: 251-287. (Pubitemid 30193850)
65. Vita JA, Treasure CB, Yeung A, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992; 85: 1390-1397.
66. Moammar MQ, Ali MI, Mahmood NA, et al. Cardiac troponin I levels and alveolar-arterial oxygen gradient in patients with community-acquired pneumonia. Heart Lung Circ 2010; 19: 90-92.
67. ver Elst KM, Spapen HD, Nguyen DN, et al. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000; 46: 650-657. (Pubitemid 30318420)
68. Mehta NJ, Khan IA, Gupta V, et al. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004; 95: 13-17. (Pubitemid 38670466)
69. Ammann P, Fehr T, Minder EI, et al. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27: 965-969. (Pubitemid 32662476)
70. Naghavi M, Wyde P, Litovsky S, et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 2003; 107: 762-768. (Pubitemid 36222607)
71. Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin Microbiol Infect 2002; 8: 2-13. (Pubitemid 34993754)
72. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000; 181: Suppl. 3, S402-S410. (Pubitemid 30416105)
73. Campbell LA, Kuo CC. Chlamydia pneumoniae - an infectious risk factor for atherosclerosis? Nat Rev Microbiol 2004; 2: 23-32. (Pubitemid 39490045)
74. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288: 2724-2731. (Pubitemid 35403786)
75. Näyhä S. Cold and the risk of cardiovascular diseases. A review. Int J Circumpolar Health 2002; 61: 373-380.
76. Keatinge WR, Donaldson GC. Cardiovascular mortality in winter. Arctic Med Res 1995; 54: Suppl. 2, 16-18.
77. Crawford VL, McNerlan SE, Stout RW. Seasonal changes in platelets, fibrinogen and factor VII in elderly people. Age Ageing 2003; 32: 661-665. (Pubitemid 37461576)
78. Woodhouse PR, Khaw KT, Plummer M, et al. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 435-439.
79. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-1099. (Pubitemid 27437871)
80. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689. (Pubitemid 36539051)
81. Chisholm J. The Read clinical classification. BMJ 1990; 300: 1092. (Pubitemid 20158094)
82. Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351: 1467-1471. (Pubitemid 28227037)
83. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-2618. (Pubitemid 39628582)
84. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008; 29: 96-103.
85. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278: 1440-1445. (Pubitemid 27475974)
86. Levy ML, Le Jeune I, Woodhead MA, et al. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Primary Care Respir J 2010; 19: 21-27.
87. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 1984; 53: 481-482. (Pubitemid 14188815)
88. Clayton TC, Capps NE, Stephens NG, et al. Recent respiratory infection and the risk of myocardial infarction. Heart 2005; 91: 1601-1602. (Pubitemid 41697605)
89. Syrjänen J, Valtonen VV, Iivanainen M, et al. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. BMJ 1988; 296: 1156-1160.
90. Lichtman JH, Fathi A, Radford MJ, et al. Acute, severe noncardiac conditions in patients with acute myocardial infarction. Am J Med 2006; 119: 843-850. (Pubitemid 44415616)
91. Lichtman JH, Spertus JA, Reid KJ, et al. Acute noncardiac conditions and in-hospital mortality in patients with acute myocardial infarction. Circulation 2007; 116: 1925-1930. (Pubitemid 350287088)
92. Zurrú MC, Alonzo C, Brescacín L, et al. Recent respiratory infection predicts atherothrombotic stroke: case-control study in a Buenos Aires healthcare system. Stroke 2009; 40: 1986-1990.
93. Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45: 158-165. (Pubitemid 47041005)
94. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47: 182-187. (Pubitemid 351920618)
95. Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalised patients with community-acquired pneumonia. Chest 2008; 134: 955-962.
96. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine 2009; 88: 154-159.
97. Vila Córcoles A. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination. J Intern Med 2009; 266: 432-444.
98. Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102: 3039-3045.
99. Keller T, Weeda VB, van Dongen CJ, et al. Influenza vaccines for preventing coronary heart disease. Cochrane Database Syst Rev 2008; 3: CD005050.
100. Horwood F, Macfarlane J. Pneumococcal and influenza vaccination: current situation and future prospects. Thorax 2002; 57: Suppl. 2, ii24-ii30. (Pubitemid 35178597)
101. Lamontagne F, Garant MP, Carvalho JC, et al. Pneumococcal vaccination and risk of myocardial infarction. CMAJ 2008; 179: 773-777.
102. Tseng HF, Slezak JM, Quinn VP, et al. Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA 2010; 303: 1699-1706.
103. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182: 1617-1623.
104. Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010; 51: 1007-1016.
105. Song Z, Brassard P, Brophy JM. A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases. Can J Cardiol 2008; 24: 391-395. (Pubitemid 351877359)
106. Chalmers JD, Short PM, Mandal P, et al. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med 2010; 104: 1081-1091.
107. Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20: 50-57.
108. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.